Shanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results

MT Newswires Live

2024/12/02

Shanghai Pharmaceuticals (HKG:2607, SHA:601607) completed the analysis of the results of the Phase II clinical trial of LT3001, a drug used for the treatment of acute stroke and acute ischemic stroke, according to a Shanghai Stock Exchange filing on Saturday.

The trial found that the drug was generally safe and well tolerated and it showed preliminary efficacy among subjects within 90 days of treatment.

The rights of the drug were bought from Shuntian Pharmaceutical Biotech in 2019 and it was approved for clinical trials in 2020, the Chinese pharmaceutical company said.

The company's shares fell 2% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2488646701"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488646701\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2488646701?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-02 13:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488646701","market":"hk","top_or_hot":-1,"title":"Shanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results","media":"MT Newswires Live","content":"<html><body><p> Shanghai Pharmaceuticals (HKG:2607, SHA:601607) completed the analysis of the results of the Phase II clinical trial of LT3001, a drug used for the treatment of acute stroke and acute ischemic stroke, according to a Shanghai Stock Exchange filing on Saturday.</p><p>The trial found that the drug was generally safe and well tolerated and it showed preliminary efficacy among subjects within 90 days of treatment.</p><p>The rights of the drug were bought from Shuntian Pharmaceutical Biotech in 2019 and it was approved for clinical trials in 2020, the Chinese pharmaceutical company said.</p><p>The company's shares fell 2% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-02 13:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shanghai Pharmaceuticals (HKG:2607, SHA:601607) completed the analysis of the results of the Phase II clinical trial of LT3001, a drug used for the treatment of acute stroke and acute ischemic stroke, according to a Shanghai Stock Exchange filing on Saturday.</p><p>The trial found that the drug was generally safe and well tolerated and it showed preliminary efficacy among subjects within 90 days of treatment.</p><p>The rights of the drug were bought from Shuntian Pharmaceutical Biotech in 2019 and it was approved for clinical trials in 2020, the Chinese pharmaceutical company said.</p><p>The company's shares fell 2% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海国资改革","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488646701","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488646701","pubTimestamp":1733118280,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Pharmaceuticals  completed the analysis of the results of the Phase II clinical trial of LT3001, a drug used for the treatment of acute stroke and acute ischemic stroke, according to a Shanghai Stock Exchange filing on Saturday.The trial found that the drug was generally safe and well tolerated and it showed preliminary efficacy among subjects within 90 days of treatment.The rights of the drug were bought from Shuntian Pharmaceutical Biotech in 2019 and it was approved for clinical trials in 2020, the Chinese pharmaceutical company said.The company's shares fell 2% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0184":"上海国资改革","BK0175":"白马股","BK0097":"医药电商","BK0099":"上海本地重组","BK0028":"国家队","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","02607":"上海医药","BK0012":"证金概念","BK0196":"行业龙头","BK0187":"一线龙头"},"translate_title":"上海制药中风患者药物试验取得积极成果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9,"02607":0.9},"content_text":"Shanghai Pharmaceuticals (HKG:2607, SHA:601607) completed the analysis of the results of the Phase II clinical trial of LT3001, a drug used for the treatment of acute stroke and acute ischemic stroke, according to a Shanghai Stock Exchange filing on Saturday.The trial found that the drug was generally safe and well tolerated and it showed preliminary efficacy among subjects within 90 days of treatment.The rights of the drug were bought from Shuntian Pharmaceutical Biotech in 2019 and it was approved for clinical trials in 2020, the Chinese pharmaceutical company said.The company's shares fell 2% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}